Management of SNRI-Induced Excessive Sweating

Understanding the Problem

Excessive sweating is a well-recognized adverse effect of SNRIs that occurs through noradrenergic and serotonergic mechanisms, with the American Academy of Child and Adolescent Psychiatry guidelines explicitly listing diaphoresis as a common SNRI adverse effect, alongside dry mouth, nausea, and other symptoms 1, 2, 3
SNRIs cause moderate to large increases in excessive sweating risk compared to placebo, with this effect being dose-dependent 4
Duloxetine specifically shows large increases in sedation and sweating as dose increases 4

Taper slowly to avoid discontinuation syndrome, which itself can cause sweating, headache, and other symptoms 1, 2

Mirtazapine has demonstrated dose-dependent reduction of SSRI/SNRI-induced sweating through its serotonin antagonistic properties, and is well-tolerated and promotes sleep 5
Bupropion is an activating antidepressant with minimal serotonergic effects, thus lower sweating risk 5, 6
SSRIs with lower sweating profiles, such as sertraline and citalopram, may have better tolerability profiles than SNRIs 7, 6
Avoid abrupt switching between antidepressants, particularly with short-acting agents like venlafaxine, desvenlafaxine, and paroxetine, which have higher discontinuation syndrome risk 8, 9

Never combine SNRIs with MAOIs due to serotonin syndrome risk, which itself presents with diaphoresis, hyperthermia, and autonomic instability 1, 2, 3
Be aware that combining multiple serotonergic agents can precipitate serotonin syndrome, where sweating is a cardinal feature 10

Monitor blood pressure and pulse regularly with all SNRIs, as they can cause sustained hypertension and tachycardia 1, 2, 3
For duloxetine specifically, monitor liver function tests due to rare but serious hepatotoxicity risk 1, 2, 3
Assess for other common SNRI adverse effects including nausea, dry mouth, and sexual dysfunction 7, 6

Older adults: SNRIs commonly cause sweating in this population; preferred alternatives include sertraline, escitalopram, or mirtazapine 7
Menopausal women: SNRIs are sometimes used to treat hot flashes, creating a paradox where low-dose venlafaxine may reduce menopausal sweating while higher doses cause it 8, 9

Do not abruptly discontinue SNRIs, as withdrawal symptoms include sweating, anxiety, dizziness, and electric shock-like sensations 1, 2
Do not ignore persistent sweating, as it leads to treatment discontinuation in 10-20% of patients in clinical trials and significantly impacts quality of life 8, 9
Do not assume all antidepressants have equal sweating risk: SNRIs have higher discontinuation rates due to adverse effects compared to SSRIs 7, 6